

# Magnus Schou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4461367/publications.pdf>

Version: 2024-02-01

72  
papers

1,775  
citations

304743

22  
h-index

302126

39  
g-index

73  
all docs

73  
docs citations

73  
times ranked

1892  
citing authors

#	ARTICLE	IF	CITATIONS
1	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [ <sup>11</sup> C]PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129.	3.9	18
2	Abstract 5977: Discovery and preclinical validation of [11C]AZ3391: A first in class blood-brain barrier permeable, subtype selective PARP-1 PET radioligand. <i>Cancer Research</i> , 2022, 82, 5977-5977.	0.9	1
3	Synthesis and Preclinical Evaluation of [ <sup>11</sup> C]AZ11895530 for PET Imaging of the Serotonin 1A Receptor. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2078-2083.	3.5	0
4	Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs. <i>Clinical Cancer Research</i> , 2021, 27, 189-201.	7.0	106
5	Brain exposure of the ATM inhibitor AZD1390 in humans: a positron emission tomography study. <i>Neuro-Oncology</i> , 2021, 23, 687-696.	1.2	35
6	Multiple Applications of a Novel Biarsenical Imaging Probe in Fluorescence and PET Imaging of Melanoma. <i>Bioconjugate Chemistry</i> , 2021, 32, 497-501.	3.6	2
7	One-Pot Synthesis of 11 C-labelled Primary Benzamides via Intermediate [11 C]Aroyl Dimethylaminopyridinium Salts. <i>Chemistry - A European Journal</i> , 2021, 27, 8689-8693.	3.3	4
8	A PET study in healthy subjects of brain exposure of <sup>11</sup> C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 799-807.	4.3	36
9	"one-pot" carbonylation: A simplified method for carbon-11 labelling of drugs and radioligands. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2020, 63, 100-107.	1.0	11
10	Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein. <i>Brain Research</i> , 2020, 1749, 147131.	2.2	21
11	Development of a fully automated low-pressure [ <sup>11</sup> C]CO carbonylation apparatus. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2020, 63, 517-522.	1.0	6
12	Transition-Metal-Free Carbon Isotope Exchange of Phenyl Acetic Acids. <i>Angewandte Chemie</i> , 2020, 132, 13592-13597.	2.0	3
13	Synthesis and Preclinical Evaluation of 6-[ <sup>18</sup> F]Fluorine-1-methyl-tryptophan, a Novel PET Tracer for Measuring Tryptophan Uptake. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1756-1761.	3.5	8
14	First Radiolabeling of a Ganglioside with a Positron Emitting Radionuclide: <i>In Vivo</i> PET Demonstrates Low Exposure of Radiofluorinated GM1 in Non-human Primate Brain. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1245-1249.	3.5	11
15	Synthesis, Biodistribution, and Radiation Dosimetry of a Novel mGluR5 Radioligand: [ <sup>18</sup> F]-AZD9272. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1048-1057.	3.5	3
16	Quantification and reliability of [11C]VC-002 binding to muscarinic acetylcholine receptors in the human lung: a test-retest PET study in control subjects. <i>EJNMMI Research</i> , 2020, 10, 59.	2.5	5
17	Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator. <i>EJNMMI Research</i> , 2019, 9, 9.	2.5	9
18	Synthesis and evaluation of two new candidate high-affinity full agonist PET radioligands for imaging 5-HT1B receptors. <i>Nuclear Medicine and Biology</i> , 2019, 70, 1-13.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Synthesis, <sup>3</sup> H-labeling and in vitro evaluation of a substituted dipiperidine alcohol as a potential ligand for chemokine receptor 2. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 265-279.	1.0	4
20	Rapid and Efficient Synthesis of <sup>11</sup> C-labeled Benzimidazolones Using [ <sup>11</sup> C]Carbon Dioxide. <i>ChemistrySelect</i> , 2019, 4, 1846-1849.	1.5	15
21	Development of a 18F-labeled PET radioligand for imaging 5-HT1B receptors: [18F]AZ10419096. <i>Nuclear Medicine and Biology</i> , 2019, 78-79, 11-16.	0.6	7
22	Visible-Light-Enabled Aminocarbonylation of Unactivated Alkyl Iodides with Stoichiometric Carbon Monoxide for Application on Late-Stage Carbon Isotope Labeling. <i>Journal of Organic Chemistry</i> , 2019, 84, 16076-16085.	3.2	26
23	Sample preparation techniques for radiometabolite analysis of positron emission tomography radioligands; trends, progress, limitations and future prospects. <i>TrAC - Trends in Analytical Chemistry</i> , 2019, 110, 1-7.	11.4	26
24	Development of [ <sup>11</sup> C]AZ13198083, a Novel Histamine Type-3 Receptor Radioligand with Favorable Kinetics. <i>ACS Chemical Neuroscience</i> , 2018, 9, 906-911.	3.5	9
25	Discovery of a Novel Muscarinic Receptor PET Radioligand with Rapid Kinetics in the Monkey Brain. <i>ACS Chemical Neuroscience</i> , 2018, 9, 224-229.	3.5	6
26	The development of a GPR44 targeting radioligand [11C]AZ12204657 for in vivo assessment of beta cell mass. <i>EJNMMI Research</i> , 2018, 8, 113.	2.5	15
27	Late-Stage Isotopic Carbon Labeling of Pharmaceutically Relevant Cyclic Ureas Directly from CO <sub>2</sub> . <i>Angewandte Chemie</i> , 2018, 130, 9892-9896.	2.0	11
28	Increased Brain Exposure of an Alpha-Synuclein Fibrillization Modulator by Utilization of an Activated Ester Prodrug Strategy. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2542-2547.	3.5	5
29	Late-Stage Isotopic Carbon Labeling of Pharmaceutically Relevant Cyclic Ureas Directly from CO <sub>2</sub> . <i>Angewandte Chemie - International Edition</i> , 2018, 57, 9744-9748.	13.8	45
30	Synthesis of trifluoromethyl moieties by late-stage copper (I) mediated nucleophilic fluorination. <i>Journal of Fluorine Chemistry</i> , 2017, 194, 51-57.	1.7	8
31	PET microdosing of CNS drugs. <i>Clinical and Translational Imaging</i> , 2017, 5, 291-298.	2.1	1
32	New methodologies for the preparation of carbon-11 labeled radiopharmaceuticals. <i>Clinical and Translational Imaging</i> , 2017, 5, 275-289.	2.1	77
33	[ <sup>11</sup> C]AZ10419096 – a full antagonist PET radioligand for imaging brain 5-HT 1B receptors. <i>Nuclear Medicine and Biology</i> , 2017, 54, 34-40.	0.6	8
34	Reduction of [ <sup>11</sup> C]CO <sub>2</sub> to [ <sup>11</sup> C]CO using solid supported zinc. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 624-628.	1.0	10
35	Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 464-471.	2.5	4
36	Efficient DBU accelerated synthesis of <sup>18</sup> F-labelled trifluoroacetamides. <i>Chemical Communications</i> , 2016, 52, 13963-13966.	4.1	13

#	ARTICLE	IF	CITATIONS
37	Direct and Efficient (Carbonyl)cobalt-Mediated Aryl Acetylation Using [ <sup>11</sup> C]Methyl Iodide. <i>European Journal of Organic Chemistry</i> , 2016, 2016, 2775-2777.	2.4	10
38	Discovery and Preclinical Validation of [ <sup>11</sup> C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor. <i>ACS Chemical Neuroscience</i> , 2016, 7, 177-184.	3.5	7
39	<sup>11</sup> C-carboxylation reactions using gas-liquid segmented microfluidics. <i>RSC Advances</i> , 2015, 5, 88886-88889.	3.6	19
40	An evaluation of a high-pressure <sup>11</sup> CO carbonylation apparatus. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 220-225.	1.0	27
41	Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv036.	2.1	34
42	Identification of positron emission tomography (PET) tracer candidates by prediction of the target-bound fraction in the brain. <i>EJNMMI Research</i> , 2014, 4, 50.	2.5	24
43	Improved Yields for the Palladium-Mediated <sup>11</sup> C-Carbonylation Reaction Using Microwave Technology. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 307-310.	2.4	19
44	Synthesis, Radiolabeling, and In Vivo Pharmacokinetic Evaluation of the Amyloid Beta Radioligand [ <sup>11</sup> C]AZD4694 in Nonhuman Primates. <i>Molecular Imaging and Biology</i> , 2014, 16, 173-179.	2.6	10
45	Determination of plasma protein binding of positron emission tomography radioligands by high-performance frontal analysis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 98, 140-143.	2.8	19
46	Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate. <i>Nuclear Medicine and Biology</i> , 2013, 40, 410-414.	0.6	14
47	Palladium-Mediated [ <sup>11</sup> C]Carbonylation at Atmospheric Pressure: A General Method Using Xantphos as Supporting Ligand. <i>European Journal of Organic Chemistry</i> , 2013, 2013, 1228-1231.	2.4	79
48	Identification of PET radiometabolites by cytochrome P450, UHPLC/Q-ToF-MS and fast radio-LC: applied to the PET radioligands [ <sup>11</sup> C]flumazenil, [ <sup>18</sup> F]FE-PE2I, and [ <sup>11</sup> C]PBR28. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 1303-1310.	3.7	25
49	Clinical Validation of <sup>18</sup> F-AZD4694, an Amyloid- $\beta$ -Specific PET Radioligand. <i>Journal of Nuclear Medicine</i> , 2012, 53, 415-424.	5.0	204
50	Radiofluorination and reductive amination using a microfluidic device. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 455-459.	1.0	14
51	Radiolabeling of two <sup>11</sup> C-labeled formylating agents and their application in the preparation of [ <sup>11</sup> C]benzimidazole. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 460-462.	1.0	6
52	Direct Plasma Metabolite Analysis of Positron Emission Tomography Radioligands by Micellar Liquid Chromatography with Radiometric Detection. <i>Analytical Chemistry</i> , 2012, 84, 3222-3230.	6.5	24
53	Synthesis and evaluation of pyridylbenzofuran, pyridylbenzothiazole and pyridylbenzoxazole derivatives as <sup>18</sup> F-PET imaging agents for $\beta$ -amyloid plaques. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4332-4337.	2.2	23
54	Rapid metabolite analysis of positron emission tomography radioligands by direct plasma injection combining micellar cleanup with high submicellar liquid chromatography with radiometric detection. <i>Journal of Chromatography A</i> , 2012, 1266, 76-83.	3.7	15

#	ARTICLE	IF	CITATIONS
55	Synthesis of a delta opioid agonist in [ <sup>2</sup> H <sub>6</sub> ], [ <sup>2</sup> H <sub>4</sub> ], [ <sup>11</sup> C], and [ <sup>14</sup> C] labeled forms. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 847-854.	1.0	8
56	Investigation of the Metabolites of (S,S)-[ <sup>11</sup> C]MeNER in Humans, Monkeys and Rats. <i>Molecular Imaging and Biology</i> , 2009, 11, 23-30.	2.6	15
57	In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [ <sup>18</sup> F]FE-PE2I, a new dopamine transporter PET radioligand. <i>Synapse</i> , 2009, 63, 871-880.	1.2	56
58	Synthesis, radiolabeling and preliminary in vivo evaluation of [ <sup>18</sup> F]FE-PE2I, a new probe for the dopamine transporter. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4843-4845.	2.2	51
59	Radiolabeling of a high potency cannabinoid subtype-1 receptor ligand, N-(4-fluorobenzyl)-4-(3-(piperidin-1-yl)indole-1-sulfonyl)benzamide (Pip1SB), with carbon-11 or 26 fluorine-18. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2008, 51, 146-152.		
60	Development of Radioligands for Imaging of Brain Norepinephrine Transporters In Vivo with Positron Emission Tomography. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1806-1816.	2.1	20
61	Synthesis of 3H-labeled N-(3-iodoprop-2E-enyl)-2 <sup>2</sup> -carbomethoxy-3 <sup>1</sup> -(4-methylphenyl)nortropine (PE2I) and its interaction with mice striatal membrane fragments. <i>Applied Radiation and Isotopes</i> , 2007, 65, 293-300.	1.5	15
62	Synthesis of 11C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for imaging central norepinephrine transporters with PET. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 616-625.	3.0	14
63	Synthesis and Positron Emission Tomography Evaluation of Three Norepinephrine Transporter Radioligands: [ <sup>11</sup> C]Desipramine, [ <sup>11</sup> C]Talopram and [ <sup>11</sup> C]Talsupram. <i>Molecular Imaging and Biology</i> , 2006, 8, 1-8.	2.6	16
64	Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[ <sup>18</sup> F]FMeNER-D2. <i>Psychopharmacology</i> , 2006, 188, 119-127.	3.1	71
65	Synthesis and PET evaluation of (R)-[S-methyl- <sup>11</sup> C]thionisoxetine, a candidate radioligand for imaging brain norepinephrine transporters. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 1007-1019.	1.0	14
66	Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[ <sup>18</sup> F]FMeNER-D2 in non-human primates. <i>Nuclear Medicine Communications</i> , 2005, 26, 695-700.	1.1	18
67	Specific in vitro binding of (S,S)-[ <sup>3</sup> H]MeNER to norepinephrine transporters. <i>Synapse</i> , 2005, 56, 100-104.	1.2	20
68	Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[ <sup>18</sup> F]FMeNER-D2. <i>European Neuropsychopharmacology</i> , 2005, 15, 517-520.	0.7	64
69	Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [ <sup>11</sup> C]RGH-1756. <i>Brain Research Bulletin</i> , 2005, 67, 219-224.	3.0	14
70	PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. <i>Synapse</i> , 2004, 53, 57-67.	1.2	105
71	A Total Synthesis of Hydroxylysine in Protected Form and Investigations of the Reductive Opening of p-Methoxybenzylidene Acetals. <i>Journal of Organic Chemistry</i> , 2004, 69, 8694-8701.	3.2	24
72	Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[ <sup>11</sup> C]MeNER. <i>Nuclear Medicine and Biology</i> , 2003, 30, 707-714.	0.6	74